Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Gideon M. Hirschfield, Pol Boudes et al.|The Lancet. Gastroenterology & hepatology|2017Cited by 186
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver diseaseManuel Romero‐Gómez, John M. Vierling|Journal of Hepatology|2023Cited by 183
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis GroupSimon Pape, Nanda Kerkar, Çiğdem Arıkan et al.|Journal of Hepatology|2022Cited by 172
Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosisAyse L. Mindikoglu, Cristian Coarfa, Antone R. Opekun et al.|Translational research|2017Cited by 79
Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 studyCynthia Levy, Alexandra Steinberg, Christopher L. Bowlus et al.|Journal of Hepatology|2020Cited by 10